Tokyo, Japan – May 11, 2026 – Daiichi Sankyo, a prominent global pharmaceutical company, has unveiled an aggressive new Five-Year Business Plan (FY2026 – FY2030) aimed at solidifying its position as a leader in oncology. The company projects revenues of over 2.3 trillion yen from its oncology division by 2030 and has set its sights on becoming a top-five global oncology player by 2035. This strategic initiative underscores a broader vision to be recognized as a “trusted healthcare innovator transforming the lives of people through science and technology.”
Accelerating Oncology Revenue and Innovation
Central to Daiichi Sankyo’s strategy is the planned launch of 20 new indications across five key medicines by 2030. The company is also focusing on identifying and developing “breakthrough generating technologies” (BGTs), such as multi-specific antibodies, targeted protein degradation, and siRNA. This R&D-centric approach is designed to expedite the delivery of innovative medicines to patients with a higher probability of success. The company aims to achieve operating profits exceeding 600 billion yen by the end of fiscal year 2030, with a target earnings per share (EPS) of over 260 yen and a consistent dividend on equity (DOE) of 10.0% or higher annually.
Driving Operational Excellence Through Technology
Beyond its research and development efforts, Daiichi Sankyo is implementing a Business Transformation Function to enhance company-wide operational efficiency. This initiative will leverage AI and digital technologies to boost productivity and optimize procurement processes, with a goal of achieving cost savings and profit improvements totaling more than 200 billion yen by 2030. Furthermore, the company plans to centralize its global commercialization activities to foster greater speed and consistency in its market strategies worldwide, while ensuring optimal resource allocation in line with its strategic priorities.
Strengthening Stakeholder Relationships
Daiichi Sankyo reaffirms its commitment to being a dependable partner for a sustainable society. The company emphasizes meaningful engagement with diverse stakeholders, including patients, employees, the medical community, and investors. By attracting specialized talent and fostering a culture of high engagement, Daiichi Sankyo aims to keep patients at the forefront of all its decisions. Strengthening trust with healthcare professionals will be achieved through the development of new standards of care supported by robust evidence generation, all while maintaining the highest compliance standards.